Literature DB >> 15527702

The role of immune tolerance in preventing and treating arthritis.

Gijs Teklenburg1, Salvatore Albani.   

Abstract

It has become increasingly clear that the innate and adaptive arms of the immune response cooperate in generating autoimmune damage in the pathogenesis of rheumatoid arthritis and juvenile idiopathic arthritis. Treatment targets the immunologic pathophysiology of the disease and is based on regaining immune tolerance. Recently introduced biological agents neutralize or simply block cytokines and their proinflammatory pathways, with favorable clinical outcome. However, major downsides are their lack of specificity and the need of continuous administration to be effective. Possibly, more can be gained from a specific approach. Indeed, recent findings suggest that targeting antigen-specific T cells can reinstate regulatory mechanisms and thus induce immune tolerization. This improved understanding has paved the way to novel immunotherapeutic approaches, some of which will be discussed here.

Entities:  

Mesh:

Year:  2004        PMID: 15527702     DOI: 10.1007/s11926-004-0022-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  58 in total

1.  Ontogeny of synonymous T cell populations with specificity for a self MHC epitope mimicked by a bacterial homologoue: an antigen-specific T cell analysis in a non-transgenic system.

Authors:  D Bonnin; B Prakken; R Samodal; A La Cava; D A Carson; S Albani
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

Review 2.  The Toll receptor family and microbial recognition.

Authors:  R Medzhitov; C Janeway
Journal:  Trends Microbiol       Date:  2000-10       Impact factor: 17.079

3.  The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.

Authors:  Todd N Eagar; Nitin J Karandikar; Jeffrey A Bluestone; Stephen D Miller
Journal:  Eur J Immunol       Date:  2002-04       Impact factor: 5.532

Review 4.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals.

Authors:  Kathleen F Nolan; Victoria Strong; Dulce Soler; Paul J Fairchild; Stephen P Cobbold; Ruth Croxton; Jose-Angel Gonzalo; Ana Rubio; Meghan Wells; Herman Waldmann
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

Review 6.  Oral tolerance for the treatment of autoimmune diseases.

Authors:  H L Weiner
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

7.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

8.  Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis.

Authors:  S Albani; E C Keystone; J L Nelson; W E Ollier; A La Cava; A C Montemayor; D A Weber; C Montecucco; A Martini; D A Carson
Journal:  Nat Med       Date:  1995-05       Impact factor: 53.440

9.  Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4.

Authors:  H Schulze-Koops; L S Davis; T P Haverty; M C Wacholtz; P E Lipsky
Journal:  J Rheumatol       Date:  1998-11       Impact factor: 4.666

10.  A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis.

Authors:  M L Barnett; D Combitchi; D E Trentham
Journal:  Arthritis Rheum       Date:  1996-04
View more
  1 in total

1.  Immunology and homeopathy. 3. Experimental studies on animal models.

Authors:  Paolo Bellavite; Riccardo Ortolani; Anita Conforti
Journal:  Evid Based Complement Alternat Med       Date:  2006-05-02       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.